Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019)

Publication

Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019)

Journal Paper/Review - Jun 14, 2019

Untch Michael, Kühn Thorsten, Luftner Diana, Maass Nicolai, Reimer Toralf, Schneeweiss Andreas, Schumacher-Wulf Eva, Schütz Florian, Thill Marc, Wuerstlein Rachel, Fasching Peter A, Kolberg-Liedtke Cornelia, Kolberg Hans-Christian, Thomssen Christoph, Bauerfeind Ingo, Braun Michael, Brucker Sara Y, Felberbaum Ricardo, Hagemann Friederike, Haidinger Renate, Hönig Arnd, Huober Jens, Jackisch Christian, Harbeck Nadia

Citation

Untch M, Kühn T, Luftner D, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thill M, Wuerstlein R, Fasching P, Kolberg-Liedtke C, Kolberg H, Thomssen C, Bauerfeind I, Braun M, Brucker S, Felberbaum R, Hagemann F, Haidinger R, Hönig A, Huober J, Jackisch C, Harbeck N. Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019). Geburtshilfe Frauenheilkd 2019; 79:591-604.

Type

Journal Paper/Review (English)

Journal

Geburtshilfe Frauenheilkd 2019; 79

Publication Date

Jun 14, 2019

Issn Print

0016-5751

Pages

591-604

Brief description/objective

The results of the international St. Gallen Consensus Conference for the treatment of patients with primary breast cancer were discussed this year by a working group of leading breast cancer experts in view of the therapy recommendations for everyday clinical practice in Germany. Three of the breast cancer experts are also members of this year's St. Gallen panel. The comparison of the St. Gallen recommendations with the annually updated treatment recommendations of the AGO 2019 as well as the S3 guideline is useful, since the recommendations of the St. Gallen panel represent the opinions of experts from various countries and disciplines. The recommendations of the S3 guideline and AGO are based on evidence-based research of the literature. This year's 16th St. Gallen conference featured the motto "Magnitude of clinical benefit". In addition to the evidence-based data, each therapeutic decision must also undergo a benefit/risk assessment of the patient's individual situation and be discussed with the patient.